Company family
Leo: medicine shortages
As of 2 Nov 2026, 3 Leo products have a reported shortage across 3 countries, covering 2 medicines.
Products short3rank #392 of 464
Medicines2active ingredients
Countries3/16
New in 90 days3+3 vs market pace
Typical duration14 daysmedian so far
Manufacturing50%demand-driven 50%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Long-run trend in Canada
Canada dashboardCanada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Tinzaparin | 2 | 13 Oct 2026 | Manufacturing problem | 2/16 | |
| Azelaic Acid | 1 | 19 Oct 2026 | Increased demand | 2/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.